Lorena Usero
Research Subjects
Lorena Usero has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Alba Orea-Soufi
1 shared publication- Carina Masferrer1 shared publication
- Carles Domènech
SL, Cerdanyola del Vallès
1 shared publication - Claudia Faundez-Vidiella
Department of Biochemistry and Molecular Biology, Institute of Neuroscience, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain
1 shared publication - Elisa Espinet
Department of Pathology and Experimental Therapy, Universidad de Barcelona Facultad de Medicina y Ciencias de La Salud, Barcelona, Spain
1 shared publication Elisabet Megias-Roda
1 shared publication
Latest Publications
- Open Access
- 22 July 2026
- Published by Elsevier in SSRN Electronic Journal
The ER stress inducer ABTL0812/ibrilatazar potentiates standard chemotherapies and mitigates the immunosuppressive microenvironment in preclinical models of pancreatic cancer
Acquired chemoresistance is common in advanced pancreatic cancer (PCa), highlighting the need to improve the efficacy of current chemotherapy regimens. In this study, we investigated the first-in-class molecule ABTL0812 (Ibrilatazar), a potent inducer of endoplasmic reticulum (ER) stress currently in clinical trial for advanced PCa, as a strategy to improve the effectiveness of standard chemotherapy.ABTL0812 enhanced the efficacy of standard chemotherapies FOLFIRINOX and gemcitabine/nab-paclitaxel in a panel of pancreatic ductal adenocarcinoma cell lines and tumor xenografts, and combined treatments showed increased levels of ER stress. ABTL0812, alone or in combination with FOLFIRINOX exerted immunomodulatory effects in the KRAS/TP53 (KPC) genetically engineered mice, by impairing the intratumoral infiltration of T regulatory (Treg) cells, the major immunosuppressive cell subset in the PCa tumors. In engrafted syngeneic PCa tumors, ABTL0812 treatment, alone or in combination with FOLFIRINOX, impaired the infiltration of Treg cells, myeloid-derived suppressor cells and exhausted CD4+/CD8+ T cells. Mechanistically, we show that ABTL0812 inhibits the differentiation of CD4+ naïve T cells into Treg cells induced by TGFb. ABTL0812 also impairs the protumoral activity of stromal cells of PCa, by inhibiting the secretion of TGFb from pancreatic stellate cells levels and of the Treg cell chemoattractant CXCL12 from patient-derived pancreatic CAFs. This work establishes that ER stress inducers such as ABTL0812 potentiate the anticancer activity of the standard chemotherapy regimens currently used in PCa, and suggests their potential to improve the effectiveness of immunotherapy.
- 22 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe ER stress inducer ABTL0812/ibrilatazar potentiates standard chemotherapies and mitigates the immunosuppressive microenvironment in preclinical models of pancreatic cancer
Acquired chemoresistance is common in advanced pancreatic cancer (PCa), highlighting the need to improve the efficacy of current chemotherapy regimens. In this study, we investigated the first-in-class molecule ABTL0812 (Ibrilatazar), a potent inducer of endoplasmic reticulum (ER) stress currently in clinical trial for advanced PCa, as a strategy to improve the effectiveness of standard chemotherapy.ABTL0812 enhanced the efficacy of standard chemotherapies FOLFIRINOX and gemcitabine/nab-paclitaxel in a panel of pancreatic ductal adenocarcinoma cell lines and tumor xenografts, and combined treatments showed increased levels of ER stress. ABTL0812, alone or in combination with FOLFIRINOX exerted immunomodulatory effects in the KRAS/TP53 (KPC) genetically engineered mice, by impairing the intratumoral infiltration of T regulatory (Treg) cells, the major immunosuppressive cell subset in the PCa tumors. In engrafted syngeneic PCa tumors, ABTL0812 treatment, alone or in combination with FOLFIRINOX, impaired the infiltration of Treg cells, myeloid-derived suppressor cells and exhausted CD4+/CD8+ T cells. Mechanistically, we show that ABTL0812 inhibits the differentiation of CD4+ naïve T cells into Treg cells induced by TGFb. ABTL0812 also impairs the protumoral activity of stromal cells of PCa, by inhibiting the secretion of TGFb from pancreatic stellate cells levels and of the Treg cell chemoattractant CXCL12 from patient-derived pancreatic CAFs. This work establishes that ER stress inducers such as ABTL0812 potentiate the anticancer activity of the standard chemotherapy regimens currently used in PCa, and suggests their potential to improve the effectiveness of immunotherapy.